Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C8EU
|
|||
| Former ID |
DAP000987
|
|||
| Drug Name |
Temozolomide
|
|||
| Synonyms |
Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Grade IV astrocytoma [ICD-11: 2A00.0; ICD-9: 191] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Schering-Plough
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H6N6O2
|
|||
| Canonical SMILES |
CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
|
|||
| InChI |
1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
|
|||
| InChIKey |
BPEGJWRSRHCHSN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 85622-93-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
225666, 465959, 5639759, 7980750, 8153316, 11407708, 11528662, 12013608, 15171582, 26719845, 29224446, 46386653, 46507934, 47207725, 49681684, 49835416, 50112682, 50112683, 53786841, 56314574, 57288569, 57322753, 78449751, 81040974, 81092891, 85246148, 92308522, 92309024, 92712460, 93166362, 99355753, 103213079, 103942738, 104309116, 117867317, 121362248, 124658873, 124800285, 125307782, 125342841, 126592898, 126625487, 126656700, 126666476, 127346798, 127548128, 131328178, 131839725, 134338257, 135035650
|
|||
| ChEBI ID |
CHEBI:72564
|
|||
| ADReCS Drug ID | BADD_D02150 | |||
| SuperDrug ATC ID |
L01AX03
|
|||
| SuperDrug CAS ID |
cas=085622931
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Temozolomide (adjusted p-values: 8.27E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7301). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.